VIP for Herniated Disc: Evidence on Repair Pathways

What's breaking down if you have Herniated disc

1. A herniation is when disc material pushes through the outer ring.
2. Often starts from degenerative disc changes — weakened annulus tears under load.
3. The herniation itself is an acute event on top of chronic degeneration.
4. Nerve compression or chemical irritation causes pain; the disc structure is still compromised.

Layers:

• Disc matrix: Collagen and proteoglycans degrade; disc height drops.
• Inflammation: Chronic inflammatory signaling without resolution stalls repair.
• Nerves: Nerve roots get irritated or compressed as disc bulges.
• Blood supply: Discs are avascular — repair depends on diffusion; less supply = slower repair.

Why VIP might help you

1. You have Herniated disc — breakdown is outpacing repair.
2. Therefore for you: If that layer is part of your problem, VIP is discussed because it targets repair (tissue) — not because it masks pain.
3. This article centers VIP; see other sections for bpc-157, tb-500, ara-290 — different layers, same condition.

Why BPC-157 might help you

1. You have Herniated disc — breakdown is outpacing repair.
2. What keeps failing: Poor blood supply at injury, weak collagen organization, slow tissue turnover.
3. What BPC-157 is studied to do: Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.
4. Therefore for you: If that layer is part of your problem, BPC-157 is discussed because it targets repair (structure / tissue) — not because it masks pain.

Why TB-500 might help you

1. You have Herniated disc — breakdown is outpacing repair.
2. Layer breaking down: Inflammation — Chronic inflammatory signaling without resolution stalls repair.
3. What TB-500 is studied to do: Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.
4. Therefore for you: If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.

Why ARA-290 might help you

1. You have Herniated disc — breakdown is outpacing repair.
2. Layer breaking down: Nerves — Nerve roots get irritated or compressed as disc bulges.
3. What ARA-290 is studied to do: Studied for nerve repair and small-fiber regeneration in neuropathy models.
4. Therefore for you: If that layer is part of your problem, ARA-290 is discussed because it targets repair (nerve / innervation) — not because it masks pain.

How these fit together

Three degeneration layers — disc/tissue, inflammation/repair cells, nerves — map to three repair pathways in the recovery stack.

• VIP → immune / autonomic
• BPC-157 → structure / tissue
• TB-500 → inflammation clearance / repair-cell migration
• ARA-290 → nerve / innervation

Primary focus of this slug: VIP. Others are in scope because the same condition breaks down on multiple layers.

What the evidence actually shows

This is a count of what is in this ledger — not a claim about all research worldwide.

• Scientific sources catalogued (PubMed, trials, reviews): 4
• Claims tagged human evidence: 3
• Claims tagged preclinical (animal/lab): 2
• Claims tagged anecdotal: 0
• Reddit posts catalogued: 0
• X posts catalogued: 0
• Other anecdote sources (YouTube, Instagram, etc.): 0
• Total sources in chain: 4

Logic: No social posts catalogued yet — we cannot report what people are saying on Reddit or X from this ledger.

Quantified confidence (this ledger): 0.54 / 1.00 — low–moderate — mostly preclinical

Formula: human claims×0.12 + preclinical×0.04 + anecdote×0.015 + studies (capped). This is not clinical certainty — it measures how much graded evidence is catalogued here.

What scientists say

Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2-Mediated Activation of Akt Signaling Pathway (source s1)

Human donor tissue and mouse model study on VIP in disc degeneration.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed · NIH

Study

Sympathetic Neurotransmitter, VIP, Delays Intervertebral Disc Degeneration via FGF18/FGFR2-Mediated Activation of Akt Signaling Pathway

Human donor tissue and mouse model study on VIP in disc degeneration.

2026-06-29 22:30s1 · #5bc2f0afdb75

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats (source s2)

Rat spinal cord injury model with BPC-157.

Evidence type: Animal or lab work — shows mechanism or early signal, not proof in people.

PubMed · NIH

Study

Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats

Rat spinal cord injury model with BPC-157.

2026-06-29 22:30s2 · #3eda2c49567d

Exogenous thymosin β4 prevents apoptosis in human intervertebral disc cells (source s3)

In vitro study on human disc cells.

Evidence type: Published research.

PubMed · NIH

Study

Exogenous thymosin β4 prevents apoptosis in human intervertebral disc cells

In vitro study on human disc cells.

2026-06-29 22:30s3 · #928647b5b136

ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (source s4)

Human trial in sarcoidosis neuropathy.

Evidence type: Tagged human evidence in this ledger — check sample size and design.

PubMed · NIH

Study

ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain

Human trial in sarcoidosis neuropathy.

2026-06-29 22:30s4 · #9a5d9ae58f16

Peptide components (collapsible embeds)

{
  "peptide": "bpc-157",
  "regenerative_layer": "structure / tissue",
  "targets_this_degeneration": "Poor blood supply at injury, weak collagen organization, slow tissue turnover.",
  "proposed_regeneration": "Studied for growing new blood vessels (angiogenesis) so repair material reaches damaged tissue.",
  "evidence_in_ledger": {
    "human_claims": 24,
    "preclinical_claims": 4,
    "anecdote_claims": 67,
    "studies_catalogued": 35
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/bpc-157"
}

{
  "peptide": "tb-500",
  "regenerative_layer": "inflammation clearance / repair-cell migration",
  "targets_this_degeneration": "Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.",
  "proposed_regeneration": "Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.",
  "evidence_in_ledger": {
    "human_claims": 14,
    "preclinical_claims": 4,
    "anecdote_claims": 74,
    "studies_catalogued": 25
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/tb-500"
}

{
  "peptide": "ara-290",
  "regenerative_layer": "nerve / innervation",
  "targets_this_degeneration": "Nerve compression, small-fiber loss, neuropathic pain signaling without tissue repair.",
  "proposed_regeneration": "Studied for nerve repair and small-fiber regeneration in neuropathy models.",
  "evidence_in_ledger": {
    "human_claims": 13,
    "preclinical_claims": 1,
    "anecdote_claims": 45,
    "studies_catalogued": 21
  },
  "confidence_0_to_1": 0.95,
  "confidence_label": "moderate (human data present)",
  "full_article": "https://miscsubjects.com/a/ara-290"
}

---

Not medical advice. Counts and quotes are from this article's hash-chained ledger. Anecdote = real reports, not proof. Animal studies ≠ human proof.